Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting

galectin therapeutics在2024年美国肝病研究协会大会上提交了3个摘要。

Benzinga · 2024/11/18 21:01

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosis
Blinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, facilitating utilization of this outcome as a critical endpoint in portal hypertension trials
Approximately a third of patients with MASH cirrhosis and portal hypertension (PH) screened for the NAVIGATE trial had the incidental finding of varices on EGD, highlighting the need for screening EGDs in these patients
NAVIGATE trial readout on track for December 2024

NAVIGATE试验的患者人群基于非侵入性检查和临床标准，利用最新的门脉高压治疗指南，适用于MASH肝硬化
对MASH肝硬化和门脉高压患者进行大型多中心试验的食管胃十二指肠镜（EGD）评估可有效建立起失明中央审查系统，促进这种结果作为门脉高压试验的重要终点的利用
约三分之一的MASH肝硬化和门脉高压（PH）患者在接受NAVIGATE试验筛查时，在EGD检查中意外发现静脉曲张，凸显了需要在这些患者中进行筛查性EGD检查
NAVIGATE试验的结果预计将于2024年12月出炉

NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and portal hypertension at the American Association for the Study of Liver Diseases (AASLD)'s annual meeting 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California.

乔治亚州诺克罗斯，2024年11月18日（环球新闻社）-- 环球凝集素治疗公司（纳斯达克：GALT）是专注于研发以凝集素蛋白为靶点的治疗药物的领先公司。今天宣布，在加利福尼亚州圣地亚哥举行的美国肝病研究协会2024年年会Liver Meeting上，关于MASH肝硬化和门脉高压患者的NAVIGATE试验的三篇海报展示。会议时间为2024年11月15日至19日。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting

Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting

风险及免责提示

声明